Evidence map›Paper›PMID 41115759›Full record

Trial reportJournal of the American Board of Family Medicine : JABFM2025

Industry Interactions at Medical Conferences: Representatives' Credentials and the Disclosure of Data Limitations Influence Clinician Perceptions.

Amie C O'Donoghue, Kathryn J Aikin, Jacqueline B Amoozegar, Mihaela Johnson, Ifeoluwa Adewumi, Douglas J Rupert

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Board of Family Medicine : JABFM, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amie C O'DonoghueFrom the Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (ACO, KJA); and RTI International (JBA, MJ, IA, DJR). Amie.Odonoghue@fda.hhs.gov).
Kathryn J AikinFrom the Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (ACO, KJA); and RTI International (JBA, MJ, IA, DJR).
Jacqueline B AmoozegarFrom the Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (ACO, KJA); and RTI International (JBA, MJ, IA, DJR).
Mihaela JohnsonFrom the Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (ACO, KJA); and RTI International (JBA, MJ, IA, DJR).
Ifeoluwa AdewumiFrom the Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (ACO, KJA); and RTI International (JBA, MJ, IA, DJR).
Douglas J RupertFrom the Office of Prescription Drug Promotion, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (ACO, KJA); and RTI International (JBA, MJ, IA, DJR).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExhibit hall booths at medical conferences are a key avenue for promoting prescription drugs to health care providers (HCPs). Because HCPs spend considerable time interacting with industry representatives at conferences, we explored how representatives' credentials might influence HCP perceptions and prescribing intentions of promoted drugs. We also examined how disclosures of clinical trial data limitations about these drugs during conference interactions might influence HCP perceptions and intentions.

methodsWe conducted a 2 × 2 factorial experimental study with HCPs (n = 430) during or immediately after their attendance at 1 of 12 US medical conferences. Participants viewed video stimuli depicting an exhibit hall interaction between an industry representative and an HCP discussing a fictitious drug for preventing nausea and vomiting. Participants were randomly assigned to 1 of 4 experimental conditions that varied (1) the representative's educational credentials (MBA vs MD) and (2) a disclosure noting clinical trial data limitations (present vs absent). Participants then completed an online questionnaire with questions about the fictitious drug, such as perceived efficacy and perceived risk.

resultsIndustry representative credentials had no influence on HCP perceptions and intentions to prescribe the drug, though representatives with medical degrees were rated as having slightly more medical knowledge. Conversely, the disclosure significantly reduced drug efficacy perceptions and led to less positive drug attitudes, although it did not influence prescribing intentions.

conclusionsThe findings suggest that HCP perceptions and intentions are not swayed by the industry representative credentials but that data limitation disclosures can temper HCP perceptions of drugs promoted at medical conferences.

Indexed as

Attitude of Health PersonnelCongresses as TopicCredentialingDisclosureDrug IndustryAdultFemaleHumansMaleMiddle AgedPrescription DrugsSurveys and QuestionnairesUnited StatesPrescription DrugsConferencesCredentialingDisclosureExhibitionHealth CommunicationIntentionPharmaceutical EconomicsPharmaceutical IndustryPharmaceuticals

Identifiers

PMID41115759
PMCPMC12978579

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.